Vaccine, typhoid


Concise Prescribing Info
Indications/Uses
Active immunisation against typhoid fever caused by Salmonella typhi
Dosage/Direction for Use
Adult : PO As enteric-coated capsule of live attenuated strain containing not less than 2 x 109 bacteria/dose: Primary immunisation: 1 cap every other day for 4 doses, at least 1 week prior to exposure. Booster dose: Repeat full course of primary immunisation every 5 years. IM As solution containing 25 mcg of Vi polysaccharide antigen/dose: Primary immunisation: 0.5 mL as a single dose via deep injection, at least 2 weeks prior to exposure. Booster dose: 0.5 mL every 3 years.
Dosage Details
Intramuscular
Active immunisation against typhoid fever caused by Salmonella typhi
Adult: As solution containing 25 mcg of Vi polysaccharide antigen/dose: Primary immunisation: 0.5 mL as a single dose via deep inj, at least 2 weeks prior to exposure. Booster dose: 0.5 mL every 3 years to patients who remain at risk.
Child: ≥2 years Same as adult dose.

Oral
Active immunisation against typhoid fever caused by Salmonella typhi
Adult: As enteric-coated capsule of live attenuated strain containing not less than 2 x 109 bacteria/dose: Primary immunisation: 1 cap every other day for 4 doses, at least 1 week prior to exposure. Booster dose: Repeat full course of primary immunisation every 5 years to patients who remain at risk.
Child: >6 years Same as adult dose.
Administration
Should be taken on an empty stomach. Take 1 hr before meals.
Contraindications
Hypersensitivity. Congenital or acquired immunodeficient state, acute febrile illness.
Special Precautions
Patient with mild acute illness, with or without fever, bleeding disorders including thrombocytopaenia. Not intended for the treatment of typhoid fever or for chronic typhoid carrier. Postpone vaccination in case of febrile or acute disease. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Syncope.
Gastrointestinal disorders: Nausea, diarrhoea, vomiting, abdominal pain.
General disorders and administration site conditions: Malaise, generalized ache, inj site reaction (e.g. tenderness, pain, induration, erythema), fever.
Musculoskeletal and connective tissue disorders: Myalgia, muscle tenderness.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Pruritus, skin rash.
Potentially Fatal: Anaphylactoid or hypersensitivity reactions.
IM/Parenteral/PO: C
MonitoringParameters
Monitor for anaphylaxis and syncope, 15 minutes after administration.
Drug Interactions
Diminished therapeutic effect with immunosuppressants. Risk of bleeding with anticoagulants.
Lab Interference
May diminish diagnostic effect of tuberculin tests.
Action
Description: Typhoid vaccine contains live attenuated strain of Salmonella typhi (Ty21a strain) as oral capsule and purified Vi capsular polysaccharide of Salmonella typhi (Ty2 strain) as solution for IM inj.
Onset: Immunity: Approx 1 week (oral); within 2 weeks (IM).
Duration: Immunity: >5 years (oral); approx 2 years (IM).
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.

ATC Classification
J07AP - Typhoid vaccines ; Used for active immunizations.
Disclaimer: This information is independently developed by MIMS based on Vaccine, typhoid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in